Cost-effectiveness of sequential treatment strategies involving first-line pembrolizumab with trastuzumab and chemotherapy for unresectable metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma

Background: Gastric cancer is a leading cause of cancer-related mortality worldwide, and HER2-positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma constitutes an aggressive molecular subtype. The KEYNOTE-811 phase III trial demonstrated improved clinical outcomes with combination the...

Full description

Bibliographic Details

Published in:	Therapeutic Advances in Medical Oncology
Main Authors:	Caicong You, Jiahao Zhang, Jianying Lei, Wu Fu, Bin Zheng, Hongfu Cai, Maobai Liu, Na Li
Format:	Article
Language:	English
Published:	SAGE Publishing 2025-09-01
Online Access:	https://doi.org/10.1177/17588359251378294